A provider can evaluate the risks and benefits based on personal health history, weight management goals, and infant feeding plans
The slowdown came fast, steadily, and relentlessly, as seen in Intuitives subsequent quarterly commentary: Q323: In bariatrics, we continued to see double digit growth albeit at a modestly lower growth rate compared to Q2 Q423: We saw a continued deceleration in growth throughout 2023, likely the result of the uptake of GLP-1 drugs. Q124: Bariatric procedure growth continued to moderate and was flat year-over-year
PMID: 40445127
Adjusting the diet to naturally boost GLP-1 activity shows promise as a strategy to improve health outcomes
It claimed 'GLP-1s for diabetes could be sold at a profit for just US $0.89 per month, compared to the price of $95 per month charged in Brazil, $115 per month charged in South Africa, $230 charged in Latvia and $353 charged in the US, which is a 39,562% markup over what the estimated generic price could be.' Christa Cepuch, Pharmacist Coordinator at MSF's Access Campaign, argues 'These new drugs are an absolute game changer for people living with diabetes, but are being kept out of the hands of hundreds of millions of people in low- and middle-income countries who need them' (Barber, Gotham, Bygrave
.webp)
&srotate=0)
